Cost-effectiveness of population-based screening for chronic kidney disease among the general population and adults with diabetes in China: a modelling study

• DOI: 10.1016/j.lanwpc.2025.101493
• Publication Date: 2025-02-17T23:43:22Z
• Authors: Fengyu Wen; Jinwei Wang; Chao Yang; Fulin Wang; Yan Li; Luxia Zhang; José A. Pagán
• Keywords: Chinese population

Despite the majority of patients with chronic kidney disease (CKD) live in low- and middle-income countries, most evidence on screening strategies is derived from high-income where contexts differ significantly. This study aims to assess cost-effectiveness population-based CKD both general population adults diabetes China. A validated microsimulation model was developed evaluate costs health consequences a societal perspective. cohort aged 45 years China simulated over their lifetime. Model parameters were estimated based existing literature various data sources Main outcomes included averted number cases cardiovascular (CVD) failure replacement therapy (KFRT) under strategy compared usual care, incremental ratios (ICERs). different frequencies for age groups considered. One-way sensitivity analyses performed robustness results. The ICER annual starting at $10,588 per quality-adjusted life year (QALY) $9184 QALY diabetes. Other also cost-effective ICERs less than three times per-capita gross domestic product ($35,501). prominent absolute decrease lifetime incidence KFRT CVD observed Specifically, decreases 1.88 8.55 1000 individuals KFRT, 35.07 19.92 CVD, respectively. could avert substantial numbers supported by grants National Natural Science Foundation (72125009), Key Research Development Program (2022YFF1203001), High Level Hospital Clinical Funding (State Laboratory Vascular Homeostasis Remodeling, Peking University, 24QZ007), University Medicine Sailing Young Scholars' Scientific & Technological Innovation (BMU2023YFJHMX014), Elite Scientists Sponsorship CAST (2022QNRC001), CAMS Fund Medical Sciences (2019-I2M-5-046).